Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials

BACKGROUND: To date, only dexamethasone has been shown to reduce mortality in coronavirus disease-19 (COVID-19) patients. Tocilizumab has been recently added to the treatment guidelines for hospitalized COVID-19 patients, but data remain conflicting. STUDY DESIGN AND METHODS: Electronic databases su...

Descripción completa

Detalles Bibliográficos
Autores principales: Selvaraj, Vijairam, Khan, Mohammad Saud, Bavishi, Chirag, Dapaah-Afriyie, Kwame, Finn, Arkadiy, Lal, Amos, Mylonakis, Eleftherios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
COVID-19 and TOCILIZUMAB
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164079/
https://www.ncbi.nlm.nih.gov/pubmed/34050796
http://dx.doi.org/10.1007/s00408-021-00451-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164079/
https://www.ncbi.nlm.nih.gov/pubmed/34050796
http://dx.doi.org/10.1007/s00408-021-00451-9

Ejemplares similares